FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3169105959> ?p ?o ?g. }

• W3169105959 abstract "The rapid growth and progression of breast tumors is driven by multiple oncogenic mutations. Of these genetic alterations, one of the most important is the increased activity of the human epidermal growth factor receptor 2 (HER2) which is present in a third of breast cancers and associated with aggressive disease and poor survival. Although new agents have improved outcomes in HER2+ breast cancer, many patients continue to progress, develop metastases and die of their disease. Novel and effective targeted therapies are urgently required to improve survival from this devastating cancer. HER2+ cancers consistently exhibit a high reliance on glycolysis to fuel their rapid growth and metastasis. The high glycolytic flux in these tumors is driven by HER2-mediated effectors including the PI3K/AKT and Ras/MAPK pathways and HIF-1α which increase glucose metabolism in part by increasing the activity of a family of enzymes termed the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFKFB1-4). The PFKFBs produce fructose-2,6-bisphosphate (F26BP) which regulates glycolysis by activating a key rate-limiting glycolytic enzyme, 6-phosphofructo-1-kinase (PFK1). In recent studies, we have found that the PFKFB4 family member is highly expressed in a series of HER2+ patient-derived breast tumors relative to normal breast tissue with markedly higher expression in their matched metastatic lymph nodes. We have determined that silencing PFKFB4 markedly reduced F26BP, glycolysis and cell survival in HER2+ breast cancer cells in vitro. We have now developeda novel and potent small molecule PFKFB4 inhibitor that selectively inhibits recombinant PFKFB4 activity, decreases glycolysis and proliferation in HER2+ breast cancer cells and limits their migration and invasion at concentrations that do not affect their viability and suppresses xenograft tumor growth in mice without systemic toxicity. During our studies, we observed that inhibition of a frequently co-expressed PFKFB family member, PFKFB3, increased PFKFB4 expression, indicating that PFKFB4 may compensate for decreased PFKFB3 expression. We now have also found that the simultaneous administration of PFKFB4 and PFKFB3 inhibitors synergistically and significantly decreases proliferation in HER2+ breast cancer cells. These observations carry additional relevance since a novel PFKFB3 inhibitor has recently completed Phase I clinical trial evaluation and compensation by PFKFB4 may limit the efficacy of this and other PFKFB3 inhibitors. Taken together, our current data indicate that targeting PFKFB4 may prove to be a successful treatment option against HER2+ breast tumors and strongly support the further exploration of co-targeting PFKFB4 and PFKFB3 as a potential therapeutic strategy to improve outcomes in this cancer." @default.
• W3169105959 created "2021-06-22" @default.
• W3169105959 creator A5020543267 @default.
• W3169105959 creator A5028609088 @default.
• W3169105959 creator A5041765132 @default.
• W3169105959 date "2021-05-01" @default.
• W3169105959 modified "2023-09-23" @default.
• W3169105959 title "Targeting Glucose Metabolism in HER2 + Breast Cancer" @default.
• W3169105959 doi "https://doi.org/10.1096/fasebj.2021.35.s1.04253" @default.
• W3169105959 hasPublicationYear "2021" @default.
• W3169105959 type Work @default.
• W3169105959 sameAs 3169105959 @default.
• W3169105959 citedByCount "0" @default.
• W3169105959 crossrefType "journal-article" @default.
• W3169105959 hasAuthorship W3169105959A5020543267 @default.
• W3169105959 hasAuthorship W3169105959A5028609088 @default.
• W3169105959 hasAuthorship W3169105959A5041765132 @default.
• W3169105959 hasConcept C104317684 @default.
• W3169105959 hasConcept C119056186 @default.
• W3169105959 hasConcept C121608353 @default.
• W3169105959 hasConcept C126322002 @default.
• W3169105959 hasConcept C20251656 @default.
• W3169105959 hasConcept C2775930923 @default.
• W3169105959 hasConcept C2779013556 @default.
• W3169105959 hasConcept C502942594 @default.
• W3169105959 hasConcept C530470458 @default.
• W3169105959 hasConcept C55493867 @default.
• W3169105959 hasConcept C62231903 @default.
• W3169105959 hasConcept C62478195 @default.
• W3169105959 hasConcept C71924100 @default.
• W3169105959 hasConcept C75217442 @default.
• W3169105959 hasConcept C86554907 @default.
• W3169105959 hasConcept C86803240 @default.
• W3169105959 hasConcept C95444343 @default.
• W3169105959 hasConceptScore W3169105959C104317684 @default.
• W3169105959 hasConceptScore W3169105959C119056186 @default.
• W3169105959 hasConceptScore W3169105959C121608353 @default.
• W3169105959 hasConceptScore W3169105959C126322002 @default.
• W3169105959 hasConceptScore W3169105959C20251656 @default.
• W3169105959 hasConceptScore W3169105959C2775930923 @default.
• W3169105959 hasConceptScore W3169105959C2779013556 @default.
• W3169105959 hasConceptScore W3169105959C502942594 @default.
• W3169105959 hasConceptScore W3169105959C530470458 @default.
• W3169105959 hasConceptScore W3169105959C55493867 @default.
• W3169105959 hasConceptScore W3169105959C62231903 @default.
• W3169105959 hasConceptScore W3169105959C62478195 @default.
• W3169105959 hasConceptScore W3169105959C71924100 @default.
• W3169105959 hasConceptScore W3169105959C75217442 @default.
• W3169105959 hasConceptScore W3169105959C86554907 @default.
• W3169105959 hasConceptScore W3169105959C86803240 @default.
• W3169105959 hasConceptScore W3169105959C95444343 @default.
• W3169105959 hasFunder F4320310177 @default.
• W3169105959 hasIssue "S1" @default.
• W3169105959 hasLocation W31691059591 @default.
• W3169105959 hasOpenAccess W3169105959 @default.
• W3169105959 hasPrimaryLocation W31691059591 @default.
• W3169105959 hasRelatedWork W1975859778 @default.
• W3169105959 hasRelatedWork W2024594909 @default.
• W3169105959 hasRelatedWork W2341949310 @default.
• W3169105959 hasRelatedWork W2438578109 @default.
• W3169105959 hasRelatedWork W2904294837 @default.
• W3169105959 hasRelatedWork W3003597902 @default.
• W3169105959 hasRelatedWork W3010300651 @default.
• W3169105959 hasRelatedWork W3216750786 @default.
• W3169105959 hasRelatedWork W4281708914 @default.
• W3169105959 hasRelatedWork W4283802633 @default.
• W3169105959 hasVolume "35" @default.
• W3169105959 isParatext "false" @default.
• W3169105959 isRetracted "false" @default.
• W3169105959 magId "3169105959" @default.
• W3169105959 workType "article" @default.